Every 424B that Benitec Biopharm (BNTC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow BNTC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BNTC filings page.
Benitec Biopharma Inc. is registering 1,481,481 shares of common stock for resale by entities affiliated with Suvretta Capital that bought these shares in a November 2025 registered direct offering. Benitec will not receive any proceeds from these secondary sales but will cover registration expenses.
The resale follows concurrent November 2025 offerings in which Benitec sold 5,930,000 shares in an underwritten deal and 1,481,481 shares in the registered direct deal at $13.50 per share, plus an additional 328,889 shares later, for aggregate gross proceeds of about $100 million. The company is a clinical-stage biotech developing BB-301, a “silence and replace” gene therapy candidate for Oculopharyngeal Muscular Dystrophy, using its DNA-directed RNA interference platform.
Entities affiliated with Suvretta Capital beneficially owned 17,952,309 shares of common stock as of February 10, 2026 and, assuming full resale of the registered shares, would beneficially own 16,470,828 shares, representing 40.9% of Benitec’s common stock.
Benitec Biopharma Inc. is registering and selling 7,411,481 shares of common stock at $13.50 per share. The deal combines a firm-commitment underwritten offering of 5,930,000 shares and a concurrent registered direct sale of 1,481,481 shares, both priced identically. The company has granted underwriters a 30‑day option to purchase up to 889,500 additional shares.
Gross proceeds reflect the pricing: the tables show proceeds to the company of $94,051,694 before expenses, and the company estimates net proceeds of approximately $93.6 million, or $104.9 million if the option is fully exercised. As of September 30, 2025, cash and cash equivalents were approximately $94.479 million. Shares outstanding were 26,250,469 as of June 30, 2025.
Benitec plans to use the net proceeds, together with existing cash, to fund continued development of its product candidate programs, working capital, and other general corporate purposes. The underwritten public offering and the concurrent registered direct offering are contingent on each other closing. The offering price represents a discount to the last reported price of $15.78 on November 5, 2025, and new investors will incur immediate dilution described in the filing.
Benitec Biopharma Inc. (BNTC) launched a mixed primary financing, comprising an underwritten offering of common stock and pre-funded warrants, alongside a concurrent registered direct offering of common stock. The prospectus also registers the shares issuable upon exercise of the pre-funded warrants. Pre-funded warrants are immediately exercisable for one share each at a $0.0001 exercise price, with beneficial ownership limits of 4.99% (or, at the holder’s election, 9.99% or up to 19.99%).
The company’s common stock last traded at $15.71 on November 4, 2025. As of September 30, 2025, cash and cash equivalents were approximately $94.479 million. Net proceeds are intended to fund continued development of product candidates, working capital and general corporate purposes. The underwritten deal includes a 30‑day option to purchase additional shares. A concurrent registered direct offering is being made to Averill entities, affiliates of Suvretta, which beneficially own approximately 49.9% of the company.